Back to Search
Start Over
Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations
- Source :
- The Journal of dermatology. 45(7)
- Publication Year :
- 2017
-
Abstract
- Generalized pustular psoriasis (GPP) is a potentially life-threatening disease that can be attributed to mutations in IL36RN in a subgroup of patients. In small trials, interleukin (IL)-17A and IL-17RA antagonists have been shown to be effective in patients with generalized pustular psoriasis in Japan. We identified seven patients who received the IL-17A antagonists secukinumab (six cases) or ixekizumab (one case) in two dermatological centers. All patients showed a good or excellent clinical response. Anti-IL-17A therapy was well tolerated and ongoing in all patients after an average therapy duration of 12.9 months. Analysis of IL36RN mutation status was performed in six patients, one patient carried a heterozygous mutation, while the other five patients did not show a mutation in IL36RN. This is the first report of a successful treatment of GPP patients without IL36RN mutations responding to anti-IL-17A therapy.
- Subjects :
- Adult
Male
medicine.medical_specialty
Heterozygote
DNA Mutational Analysis
Dermatology
Disease
Antibodies, Monoclonal, Humanized
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Japan
Medicine
Humans
Psoriasis
Aged
Retrospective Studies
business.industry
Interleukins
Interleukin-17
Interleukin
Antibodies, Monoclonal
General Medicine
Middle Aged
medicine.disease
3. Good health
Ixekizumab
Treatment Outcome
030220 oncology & carcinogenesis
Mutation (genetic algorithm)
Mutation
Generalized pustular psoriasis
Clinical Global Impression
Secukinumab
Female
Interleukin 17
Dermatologic Agents
business
Subjects
Details
- ISSN :
- 13468138
- Volume :
- 45
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- The Journal of dermatology
- Accession number :
- edsair.doi.dedup.....0fad6839c0386cc85498603c876523de